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Abstract Peroxisome proliferator activated receptor Q (PPARQ)
is the subject of intense investigation as a target for drugs against
diabetes, atherosclerosis and cancer. For this reason there is
considerable interest in the spectrum of compounds that bind this
receptor. In this paper we have identified cis-parinaric acid
(CPA) as a novel hPPARQ ligand. The binding of this fatty acid
to the receptor increases its fluorescence and causes a shift in the
UV spectrum. This spectral shift is reversible by competition with
other known ligands for PPARQ. This report represents the first
direct demonstration of a fatty acid binding to PPARQ.
z 1998 Federation of European Biochemical Societies.
Key words: Peroxisome proliferator; Anti-diabetes drug;
Fatty acid; Fluorescence; Spectrophotometry;
Nuclear receptor
1. Introduction
The peroxisome proliferator activated receptors (PPARs)
belong to the nuclear receptor family of ligand activated tran-
scription factors and function as molecular switches, binding
fatty acids and a wide range of xenobiotics to activate tran-
scription of responsive genes [1,2]. Several physical changes
may occur after ligand binding to such nuclear receptors,
and these include increased DNA binding through heterodi-
merisation with the retinoid X receptor [1] as well as increased
interactions with co-activator proteins such as SRC-1 [3].
PPARs have been shown to control target genes involved in
lipid metabolism and energy balance in response to fatty acids
and eicosanoids [4^7]. One member of this family, PPARK, is
activated by the ¢brate family of hypolipidemic drugs and is
expressed at high levels in the rodent liver [8]. PPARK also
mediates the pathological phenomenon known as peroxisome
proliferation, that is caused by ¢brate drugs in the rodent
liver. The absolute requirement for PPARK in these events
has been con¢rmed using mice containing a targeted disrup-
tion of the PPARK gene [9]. PPARQ is another member of this
subfamily of nuclear receptors, which is expressed at high
levels in adipose tissue and has been shown to be an impor-
tant regulator of adipocyte di¡erentiation [10]. PPARQ is ac-
tivated by the isoprostanoid 15-deoxy v12;14-PGJ2 and the
thiazolidenedione family of insulin sensitising drugs which in-
clude troglitazone and BRL 49653 [11^13]. PPARQ is also
expressed in other tissues such as colon, bone marrow, leuko-
cytic cell lines and T-cells [14]. The expression of PPARQ in
activated macrophages has recently been linked with the anti-
in£ammatory action of thiazolidenedione drugs and ¢sh oil-
derived polyunsaturated fatty acids [15,16]. PPARQ has also
been implicated in the anti-neoplastic properties of certain
polyunsaturated fatty acids and has been shown to mediate
withdrawal from cell cycle in transformed ¢broblasts, liposar-
coma and human breast cancer cell lines [17^20].
cis-Parinaric acid (CPA) is a naturally occurring polyun-
saturated fatty acid which is selectively toxic to tumour cell
lines in vitro [21,22]; however, the molecular target for this
selective toxicity is not known.
The £uorescent properties of CPA have been used to study
its binding to fatty acid binding proteins [23^25]. This fatty
acid is relatively non-£uorescent in aqueous environment,
however, in a hydrophobic environment, such as in the lipid
binding site of a protein, CPA becomes £uorescent. CPA also
has a distinct UV spectrum which is shifted by the binding of
proteins such as albumin [26]. We have exploited these phe-
nomena in order to demonstrate the binding of this fatty acid
to recombinant human PPARQ, and have shown that CPA
binds hPPARQ with a high a⁄nity. In addition, the spectral
properties of the PPAR/CPA complex have allowed us to
develop a simple method for the screening for novel PPAR
ligands.
2. Materials and methods
2.1. Isolation of a cDNA human PPARQ ligand binding domain
An 877-bp portion of the human PPARQ cDNA encoding the li-
gand binding domain (hPPARQLBD, amino acids 195^478) was iso-
lated by PCR from a human kidney cDNA library (Clonetech) using
the following primers. Primer A: 5P-CGGGATCCATATGGCGGA-
GATCTCCAGTGATATCG-3P ; primer B: 5P-CGGGATCCCTAG-
TACAAGTCCTTGTCCTTGTAGATCTCCTGC-3P. The ampli¢ca-
tion product was cloned into pET15b. Primer A generated an NdeI
site/ATG initiation codon at the 5P end of the product and primer B
introduced a BamHI site immediately after the terminator codon. The
ampli¢ed products were digested with NdeI/BamHI and ligated into
NdeI/BamHI digested pET15b. This ligation was transformed into E.
coli strain XL-1 Blue. Complete sequencing of the cloned DNA re-
vealed that it encodes a protein that is identical to those encoded by
previously published cDNAs.
2.2. Expression of hPPARQ ligand binding domains in E. coli
The pET15b-hPPARQLBD plasmid was transformed into E. coli
strain BL21(DE3) pLYSs. Expression of the His-tagged hPPARQLBD
was induced with 0.5 mM IPTG at 30‡C for 3 h. Lysates from these
cultures were prepared by previously described methods [5] in PBS
containing glycerol (10%), phenylmethylsulfonyl £uoride (0.2 mM)
and L-mercaptoethanol (5 mM) and then loaded onto a nickel agarose
column (1 ml resin per litre of culture) at a £ow rate of 1^2 ml/min.
The column was then washed with 30 column volumes of loading
bu¡er containing 10 mM imidazole (pH 8.8) followed by 10 column
volumes of loading bu¡er containing 25 mM imidazole (pH 8.8). The
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hPPARQLBD protein was eluted with loading bu¡er containing 250
mM imidazole (pH 8.8). The imidazole was removed and the protein
was concentrated using a Centricon concentrator (10 K cut o¡). Any
aggregated protein was then removed by ultracentrifugation at
100 000Ug for 1 h. The glycerol concentration in the ¢nal protein
preparation was increased to 50% (v/v) and aliquots were stored at
320‡C. The protein preparations stored in this manner were active for
at least nine months. Most of the data presented in this manuscript
are, however, derived from freshly prepared protein, stored at 4‡C for
less than 3 days.
2.3. Handling and storage of CPA
CPA was obtained from Molecular Probes, Eugene, OR, USA. Due
to the susceptibility of CPA to oxidation, CPA was purchased in
special 10-mg aliquots which were stored at 320‡C. Aliquots were
resuspended, as required, in DMSO and the concentration of CPA
in stock solutions was con¢rmed before each procedure using the
extinction coe⁄cient at 304.2 nm in ethanol of 78 000 [26]. Solutions
of CPA were stored in the short term (less than one month) at 320‡C
under nitrogen.
2.4. CPA £uorescence assays
Puri¢ed hPPAR LBD protein was mixed with CPA in 25 mM Tris-
HCl, pH 7.5 at room temperature and the resulting £uorescence was
measured immediately using a Perkin Elmer LS-3 £uorescence spec-
trophotometer (excitation wavelength of 318 nm and emission wave-
length of 410 nm). The £uorescence resulting from protein alone and
CPA acid alone were totalled and deducted from the measured value.
2.5. CPA spectrophotometric assays
CPA was added to 25 mM Tris-HCl, pH 7.5, at room temperature
and scanned against bu¡er between 312 nm and 340 nm using a
Shimadzu UV-3000 scanning spectrophotometer. All subsequent ad-
ditions of protein and competitor compounds were added equally to
both the sample and reference cuvettes. Incorporation of up to 2%
DMSO did not produce any signi¢cant changes in the observed spec-
tra and this was the maximum used in the addition of competitor
compounds. Binding constants were calculated using a single binding
site curve ¢tting with Ultra¢t for the Macintosh. The resulting Ki
values and the standard error of values derived from 2^4 independent
experiments is presented in the text. Fatty acids and ibuprofen were
obtained from Sigma, and 15-deoxy v12;14-PGJ2 was obtained from
the Cayman Chemical Company (Ann Arbor, MI, USA).
3. Results
The cDNA encoding the hPPARQ ligand binding domain
(PPARQLBD) was isolated by PCR from a human kidney
cDNA library. This cDNA encoded a protein that was iden-
tical to the published human PPARQ protein sequences [14].
The pET15b expression vector gave high levels of histidine-
tagged recombinant protein in E. coli which facillitated the
a⁄nity puri¢cation of large amounts of highly puri¢ed
PPARQLBD (V20 mg per litre of culture). These preparations
were greater than 90% pure as judged by scanning Coomassie
blue-stained SDS-PAGE gels (data not shown).
A⁄nity puri¢ed recombinant protein was assayed for bind-
ing to the £uorescent fatty acid CPA (Fig. 1). The
PPARQLBD displayed limited intrinsic £uorescence at the
protein concentrations studied (Fig. 1A, open squares). How-
ever, inclusion of CPA resulted in a much greater £uorescent
signal that was dependent on the presence of PPARQLBD and
CPA (Fig. 1A, open diamonds). Subtraction of the intrinsic
£uorescence of the PPARQLBD demonstrated that the £uo-
rescence of CPA increased with increasing concentrations of
PPARQLBD and this observed £uorescence was saturable
(Fig. 1B). This revealed that CPA has a Kd of 669 þ 75 nM
for binding to PPARQLBD. This is a high a⁄nity interaction
that is tighter and therefore more speci¢c than was observed
for CPA binding to the adipocyte lipid binding protein or
bovine serum albumin (both having a Kd V2 WM) [25,26].
Puri¢ed trypsinogen was used as a negative control and no
binding of CPA was observed (data not shown).
CPA has a distinct UV spectrum at 319 nm and this is
shifted to 324 nm on binding to proteins such as albumin.
This phenomenon has been exploited to quantitate free fatty
acids in serum as the spectral shift is reversible by competition
[26]. Inclusion of PPARQLBD in solutions containing CPA
resulted in a shift of the CPA spectrum resulting in a peak
at 324 nm (Fig. 2). This shift was dependent on the concen-
tration of both CPA and PPARQLBD in a manner that cor-
relates with the binding relationships observed using the £uo-
rescence assay. The spectral change was also reversible with
the addition of the high a⁄nity PPARQ ligand, BRL 49653.
This magnitude of the spectral shift can be quanti¢ed by
determining the ratio of the absorbancies at 319 nm and 329
nm [26]. The 319/329 ratio of CPA in solution is between 2.6
and 3 and the ratio for the CPA which is fully bound to
receptor is 1. Using low concentrations of CPA, that are be-
low the apparent Kd, it can be seen that increasing levels of
PPARQLBD reduce the 319/329 ratio from 2.6 to a plateau of
1.6 (Fig. 3A). This curve con¢rms a Kd of approximately 600
nM. The ratio never reaches 1 in this assay as the low con-
centration of the CPA does not allow for complete binding of
the fatty acid to the PPARQLBD. In assays utilising higher
concentrations of both CPA and PPAR a ratio of 1 was
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Fig. 1. CPA binds hPPARQ with a high a⁄nity. The structure of
CPA is shown. A: Fluorescence of increasing concentrations of pu-
ri¢ed hPPARQLBD was monitored in the presence (diamonds) and
absence (squares) of CPA (300 nM) as described in Section 2. B:
Shown is a plot with the intrinsic protein £uorescence subtracted
from the £uorescence obtained in the presence of CPA. A Kd of
669 þ 75 nM is observed. As a negative control, trypsinogen (5 WM)
was added to 300 nM CPA and this did not result in any increased
£uorescence (data not shown). Each point shown is a mean value
obtained from 2^4 independent experiments.
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achieved (Fig. 2). In order to establish the speci¢city of bind-
ing and to further validate the assay, we investigated whether
known PPARQ ligands would compete for binding. In these
assays PPARQLBD (2 WM) and CPA (1.5 WM) were used to
give a ¢nal 319/329 ratio of approximately 1.2. Using these
conditions, competition with BRL 49653 was observed with a
Ki of 2.19 þ 0.3 WM. This value is not signi¢cantly di¡erent
from the concentration of the PPARQLBD in the assay (2
WM) and therefore does not re£ect the true a⁄nity of BRL
49653, rather this value re£ects the stoichiometry of BRL
49653 binding to the PPARQLBD (Fig. 3B, squares). The in-
trinsic Kd of BRL 49653 for PPARQ is 40 nM [11,13]. In order
to accurately measure such a low Kd it would be necessary for
both CPA and PPARQLBD to be present in the assay at less
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Fig. 2. CPA has a UV spectrum that is shifted by binding to
hPPARQ. The sequential UV spectra shown are: CPA alone: CPA
(3 WM) in solution. The CPA in solution has a 319 nm/329 nm ratio
of 3 due to the peak at 319. CPA+PPAR: hPPARQLBD protein (5
WM) was then added to both the reference and sample cuvettes.
This resulted in shifting of the peak to 324 nm and resulted in a
319 nm/329 nm ratio of 1. CPA+PPAR+BRL: A large excess of
the thiazolidenedione drug BRL 49653 (50 WM) was then added to
both the sample and reference cuvettes. This resulted in the dis-
placement of CPA, shifting the peak back towards 319 nm and pro-
ducing a ratio of 2.6.
C
Fig. 3. A displacement assay for PPARQ ligands. The structures of
compounds used in the displacement assay are shown. A: Titration
of CPA with hPPARQ. Increasing concentrations of hPPARQLBD
protein were added to 500 nM CPA and the 319 nm/329 nm ratio
determined as described in Section 2. B: Displacement of CPA
binding to hPPARQ by the high a⁄nity ligand BRL 49653 and the
isoprostanoid 15-deoxy v12;14-PGJ2. Increasing concentrations of
BRL 49653 (open squares) and 15-deoxy v12;14-PGJ2 (open dia-
monds) were added to cuvettes containing 1.5 WM CPA and 2 WM
hPPARQ. Shown is the relative drop in 319/329 ratio compared to
fully bound. The BRL 49653 plot is a representative experiment of
two independent experiments. The 15-deoxy v12;14-PGJ2 shows three
independent experiments plotted together to demonstrate the repro-
ducibility of the assay. C: Displacement of CPA binding to hPPARQ
by docosahexanoic acid, oleic acid, nafenopin and stearic acid. In-
creasing concentrations of docosahexanoic acid (diamonds), oleic
acid (triangles), nafenopin (¢lled squares), stearic acid (open
squares) were added to cuvettes containing 1.5 WM CPA and 2 WM
hPPARQ. Shown is the relative drop in 319/329 ratio compared to
CPA fully bound to PPAR. Each plot is a representative experiment
of 2^4 independent experiments. D: Displacement of CPA binding
to hPPARQ by Q-linolenic acid, eicosapentanoic acid and linoleic
acid. Increasing concentrations of Q-linolenic acid (open squares), ei-
cosapentanoic acid (¢lled squares), linoleic acid (diamonds) and ibu-
profen (triangles) were added to cuvettes containing 1.5 WM CPA
and 2 WM hPPARQLBD. Shown is the relative drop in 319/329 ratio
compared to CPA fully bound to PPAR. Each plot is a representa-
tive experiment of 2^4 independent experiments.
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than 10 nM. Under these conditions, however, the CPA and
PPARQLBD would be completely dissociated and could not
serve as a reporter system.
Displacement of CPA was also observed using a proposed
endogenous ligand, 15-deoxy v12;14-PGJ2 with a Ki of 6.4 þ 0.9
WM (Fig. 3B, diamonds). The PPARK ligand and peroxisome
proliferator nafenopin has a very poor a⁄nity for this recep-
tor of 128 þ 10 WM (Fig. 3C, ¢lled squares). The NSAID,
ibuprofen was also a very poor ligand for the PPARQLBD
with a Ki of 329 þ 50 WM (Fig. 3D, triangles). This value
agrees well with the concentrations required to elicit PPARQ
activity in human macrophages (EC50 = 140^450 WM) [15]. The
saturated fatty acid, stearic acid, did not displace CPA from
PPARQLBD at concentrations up to 200 WM (Fig. 3C, open
squares). Beyond this concentration stearic acid was insoluble.
Polyunsaturated fatty acids such as docosahexanoic acid
(Fig. 3C, diamonds, Ki = 2.93 þ 0.3 WM), Q-linolenic acid
(Fig. 3D, open squares, Ki = 2.28 þ 0.1 WM), and eicosapenta-
noic acid (Fig. 3D, ¢lled squares, Ki = 3.1 þ 0.2 WM) displaced
CPA from PPARQLBD at concentrations similar to the con-
centration of PPARQLBD in the assay; whereas oleic acid and
linoleic acid have lower Kis of 11.7 þ 0.5 and 8.37 þ 0.8, re-
spectively (Fig. 3C, triangles and Fig. 3D, diamonds).
4. Discussion
In the present study we have shown CPA to be a novel
ligand for human PPARQ that has a high a⁄nity for this
receptor with a Kd of 669 nM. This is the ¢rst report of fatty
acids binding to human PPARQ. The spectral properties of
CPA have been used to develop an assay for the binding of
fatty acids and drugs to the human PPARQ. Previous ligand
binding studies for PPARs have utilised radiolabelled com-
pounds that are not widely available or have utilised indirect
methods based on protein/protein interactions [1^3,11]. In
contrast to these methods, the assay presented in this report
only requires a simple 2 point spectrophotometric determina-
tion and utilises reagents and equipment that are readily avail-
able. Very high and low a⁄nity ligands can be identi¢ed by
this assay. This assay therefore serves as a valuable initial
screen in the discovery of new ligands.
There are a few reports on fatty acid binding to proteins
related to hPPARQ. Previous studies have examined binding
of polyunsaturated fatty acids to Xenopus and mouse PPARQ
using radioligand displacement and indirect protein/protein
interaction assays. The a⁄nity of CPA for hPPARQ is slightly
higher than that reported for the proposed natural ligand 15-
deoxy v12;14-PGJ2 binding to mouse PPARQ as measured by
the displacement of radiolabelled BRL 49653 (Ki = 2.5 WM).
This study has shown that the human PPARQLBD has a
a⁄nity for this ligand of 6.4 WM which is comparable to the
concentrations required for the stimulation of lipogenesis in
murine ¢broblasts (EC50 = 7 WM) [12]. In the Xenopus system
two widely di¡erent values have been determined. The a⁄nity
of 15-deoxy v12;14-PGJ2 for the xPPARQ was measured to be
500 nM by the displacement of radiolabelled ¢brate, GW2331
[2] and approximately 15 WM by the activation of co-receptor
binding in vitro [3]. The variations between studies presum-
ably re£ect the di¡erent assays used in each case.
Species di¡erences have been seen for the activation of oth-
er human and Xenopus PPARs [27]. This report has demon-
strated that hPPARQ has a high a⁄nity for several essential
fatty acids such as Q-linolenic acid, eicosapentanoic acid and
docosahexanoic acid when compared to the xPPARQ and a
lower a⁄nity for fatty acids that are abundant in the human
diet such as linoleic acid and oleic acid [2,3]. Such species
di¡erences presumably re£ect the di¡erences in diet and phys-
iology that occur between frogs and man.
The binding of these dietary fatty acids at low micromolar
concentrations is in the same range, or tighter than 15-deoxy
v12;14-PGJ2. These essential fatty acids therefore represent
high a⁄nity ligands for hPPARQ. The presence of these com-
pounds in the diet would suggest that they may have an im-
pact on the activation status of PPARQ in man. It is therefore
important that future studies on essential fatty acid supple-
mentation in man should consider the possibility that any
observed e¡ects may be mediated by this novel receptor sys-
tem.
In conclusion, we have presented the ¢rst direct demonstra-
tion of fatty acid binding to hPPARQ and have developed a
simple assay that allows the identi¢cation of potential agonists
and antagonists of PPARQ function. This screening method
may facilitate the discovery of a large number of novel natural
compounds and pharmaceuticals for the treatment of diabe-
tes, atherosclerosis and cancer.
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